<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599507</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-047</org_study_id>
    <nct_id>NCT01599507</nct_id>
  </id_info>
  <brief_title>Study of FG-4592 in Subjects With Chronic Kidney Disease in China</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the&#xD;
      correction of anemia in non-dialysis chronic kidney disease patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose ranging study with two consecutive dose escalation cohorts. The study objective is to&#xD;
      demonstrate that FG-4592 is effective in the correction of anemia in chronic kidney disease&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change in hemoglobin by Week 9 from baseline</measure>
    <time_frame>Week 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a target Hb level ≥11 g/dL by Weeks 5,6,7,8 and 9.</measure>
    <time_frame>Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a Hb increase from baseline ≥1.0 g/dL.</measure>
    <time_frame>Week 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Anemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>FG-4592</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>TIW dosing, capsule</description>
    <arm_group_label>FG-4592</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TIW dosing, capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years&#xD;
&#xD;
          2. Subject has voluntarily signed and dated an informed consent form&#xD;
&#xD;
          3. Chronic Kidney Disease, not receiving dialysis&#xD;
&#xD;
          4. Hemoglobin (Hb) values in 4 screening visits and the mean Hb must be &lt;10g/dL&#xD;
&#xD;
          5. Aminotransferase levels (alanine aminotransferase [ALT], aspartate aminotransferase&#xD;
             [AST]) and total bilirubin must be ≤ upper limit of normal (ULN) during the screening&#xD;
             period&#xD;
&#xD;
          6. Serum alkaline phosphatase (ALP) ≤2x ULN during screening period. Subjects with serum&#xD;
             ALP values between 1 x and 2 x ULN may be included only if bone-specific ALP (BSAP) is&#xD;
             also elevated &gt; ULN&#xD;
&#xD;
          7. Total bilirubin values must be ≤ULN during screening period&#xD;
&#xD;
          8. Serum folate and vitamin B12 levels above the lower limit of normal (LLN)&#xD;
&#xD;
          9. Body weight: 40 to 100 kg (dry weight) inclusive&#xD;
&#xD;
         10. Body mass index (BMI): 16 to 38 kg/m2 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any erythropoiesis-stimulating agent (ESA) other than epoetin alfa within 12&#xD;
             weeks prior to Day 1&#xD;
&#xD;
          2. Any clinically significant infection or evidence of an underlying infection such as a&#xD;
             white blood cell count (WBC) &gt; ULN during screening on two separate occasions,&#xD;
&#xD;
          3. Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B&#xD;
             surface antigen (HBsAg); anti-hepatitis C virus antibody (anti-HCV Ab)&#xD;
&#xD;
          4. History of chronic liver disease&#xD;
&#xD;
          5. New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          6. Chronic inflammatory disease other than glomerulonephritis that could impact&#xD;
             erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac&#xD;
             disease) even if it is currently in remission&#xD;
&#xD;
          7. Active or chronic gastrointestinal bleeding, or a known coagulation disorder&#xD;
&#xD;
          8. Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types,&#xD;
             etc.)&#xD;
&#xD;
          9. Hematological disorders, including myelodysplastic syndrome, multiple myeloma, or pure&#xD;
             red cell aplasia&#xD;
&#xD;
         10. History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric&#xD;
&#xD;
         11. Active hemolysis or diagnosis of hemolytic syndrome&#xD;
&#xD;
         12. Known bone marrow fibrosis&#xD;
&#xD;
         13. Uncontrolled or symptomatic secondary hyperparathyroidism (PTH&gt;600ng/L)&#xD;
&#xD;
         14. Any prior organ transplantation&#xD;
&#xD;
         15. Drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal&#xD;
             condition that may lead to reduced absorption of study drug&#xD;
&#xD;
         16. Serum albumin &lt;3 g/dL&#xD;
&#xD;
         17. History of alcohol or drug abuse; or a positive drug screen for a substance that has&#xD;
             not been prescribed for the subject&#xD;
&#xD;
         18. Prior treatment with FG-4592&#xD;
&#xD;
         19. Use of an investigational medication or treatment, or carryover effect of an&#xD;
             investigational treatment expected, during the screening visit, treatment and&#xD;
             follow-up period.&#xD;
&#xD;
         20. Use of traditional Chinese medicines (TCM) during the screening visit to Day 1 or&#xD;
             plans to use TCM during the study unless approved in advance by the Medical Monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First affiliated hospital of Dalian medical university</name>
      <address>
        <city>DaLian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang University No 1. Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Zheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XinHua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Renal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

